Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners（2023）
摘要
The management of AEs is crucial for adherence and maintaining the dose intensity of lenvatinib in elderly HCC patients.
更多查看译文
关键词
Hepatocellular carcinoma,elderly,lenvatinib,tolerability
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要